Arctoris appoints three experienced industry executives to Advisory Board

Arctoris, an Oxford-based research company operating a fully automated drug discovery platform, has appointed three distinguished experts as members of its Advisory Board: Beth J Hoffman PhD, Prof. Khusru Asadullah MD, and Stanley Lapidus.

“We are delighted to see Dr Hoffman, Prof Asadullah and Mr Lapidus join our company’s Advisory Board at this exciting moment in Arctoris’ growth,” said Martin-Immanuel Bittner MD DPhil, CEO and Co-Founder of Arctoris. “Each of them brings deep industry knowledge and expertise that will be instrumental in executing our plans to become the global leader for roboticspowered drug discovery.”

Hoffman is a seasoned pharmaceutical and biotech executive and bring invaluable experience in drug discovery and development, both from the R&D and business perspective. She is the CEO of San Diegobased Origami Therapeutics. During her distinguished career she has also served as vice-president of Discovery Biology at Vertex Pharmaceuticals and held leadership positions at Amgen, Eli Lilly, and the NIH.

Prof Asadullah is a renowned academic and an authority in translational medicine with more than 15 years of industry experience. He was the vice-president and head of Target Discovery at Bayer. In this role, he led the industry-changing Bayer reproducibility study, which challenged the status quo in drug target identification. Prof Khusru will advise Arctoris in translational and precision medicine, data standards, and best practices in drug discovery.

Lapidus is founder and former CEO of the CYTYC Corporation, founder and former chairman and CEO of Exact Sciences, and Executive in Residence at the University of Colorado. He is a serial entrepreneur who brought two companies from idea to NASDAQ, and has unparalleled insights in the life sciences, biotech, and medtech arena. Lapidus will support the management and the Board of Arctoris in developing and executing its global growth strategy.

Commenting on the appointments, Hoffman said: “On behalf of my two colleagues, I am honoured to join the Arctoris Advisory Board. I have spent several decades in drug discovery, and I believe it is time for a radically different approach that will allow us to generate better data faster and to accelerate the translation of new hypotheses into new drugs. Arctoris developed a unique technology platform, and assembled a world-class team to transform data generation in this space.

“I am proud to support Arctoris on its mission, and look forward to working with the company’s management and Board.”

Arctoris has established the world’s first fully automated drug discovery platform, offering pre-optimized and fully validated processes for its partners and customers globally. Accessible remotely, the platform provides on-demand access to a wide range of biochemical, cell biology and molecular biology assays conducted by robotics, enabling rapid, informed decision-making in basic biology, target validation, toxicology and phenotypic screening.